Supplied formLinear 15-residue peptide; free-base and acetate forms require separate specification
Lead time7–14 days
Representative packaging image · verify the ordered lot
Decision summary
Key benefits
Research applications include peptide identity and metabolism, gastric and intestinal injury models, tendon/ligament and other tissue-repair models, angiogenesis and nitric-oxide-related readouts, inflammation models and preclinical neural-injury research
Relative publication volume does not establish human therapeutic benefit.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.
Qualification data
Specifications to confirm against the released lot
CAS
137525-51-0
Formula
C62H98N16O22
Molecular weight
1419.5 g/mol
Appearance
Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-batch COA
Purity
≥ 99.0% · target, verify batch COA
Storage
Follow the released lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, buffer, concentration, container and any post-reconstitution hold time require stability-indicating evidence for the exact free-base or acetate form. Do not assign a universal frozen shelf life or 28-day solution period.
Identity, purity and content are separate release questions.
Identity
Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.
Purity
Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.
Content
Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.
Stability
Follow the storage condition stated on the batch COA or label from receipt onward.
Research context
What researchers study about BPC-157
BPC-157 is a synthetic linear 15-residue peptide, GEPPPGKPADDAGLV, associated with the “stable gastric pentadecapeptide” research literature. Most evidence is preclinical and includes gastrointestinal-injury, tissue-repair, inflammatory and nervous-system animal models. PubChem also links the name to an investigational record, but BPC-157 is not an approved finished medicine. A 2025 uncontrolled report in 2 healthy adults is far too small to establish human efficacy, dose or long-term safety. As of 15 July 2026, FDA has scheduled BPC-157 free base and acetate for 503A Bulks List advisory discussion on 23 July 2026; a scheduled non-binding review is not approval. The 2026 WADA list prohibits BPC-157 under S0.
Laboratory topics include gastrointestinal cytoprotection models, tissue-repair and angiogenesis models, inflammatory signaling, peptide metabolism and preclinical nervous-system injury
These are research applications, not approved indications or graded human efficacy claims.
Mechanism context
The question the literature is testing
Animal and cell studies propose effects involving angiogenesis, nitric-oxide signaling, endothelial pathways, growth-factor expression and cytoprotection. No single validated molecular receptor or target explains all reported findings, and route- or injury-site claims are not established in humans. Mechanistic studies require direct target, pathway and orthogonal comparator controls.
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.
Evidence boundaries
Compatibility, limitations and decision context
Not approved for human or veterinary use
Animal toxicology and a 2-person uncontrolled human report cannot establish broad safety, contraindications, reproductive risk, adverse-event frequency or long-term outcomes
FDA review materials and the pending advisory process highlight the need for rigorous identity, impurity, aggregation and immunogenicity assessment
WADA prohibits BPC-157 under S0 for covered athletes
Laboratory work should follow the lot SDS and institutional controls; this catalogue provides no injection, anticoagulant, pregnancy or monitoring advice.
Interactions reported in the literature
No controlled evidence establishes synergy or compatibility with TB-500, growth-hormone-axis peptides, GLP-1/GIP medicines, copper peptides or other materials
Any co-formulation requires blend-specific analytical, stability, uniformity and compatibility development; theoretical pathway complementarity is not a recommendation.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.
Batch documentation
BPC-157 batch COAs
Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount
2 mg
5 mg
10 mg
Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.
Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.
Third-party reports, added progressively
Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.
Help reviewing your COA
Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.
On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep
Third-party reports for BPC-157
Reports from Qorix (tjqxgd.com), a third-party analytical laboratory in Tianjin, China: HPLC purity and MS identity of the sample tested.
Laboratory: Third-party laboratoryTests: HPLC purity · MS identity
5 mg
10 mg
Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.
Ask for the current packet, not a generic certificate
Specify free base or acetate, complete 15-residue sequence, termini, counterion, formula and molecular-weight basis
Require lot traceability, theoretical and high-resolution observed intact mass, sequence-level evidence where appropriate, a stability-indicating chromatographic purity and impurity profile, quantitative peptide content, water, counterion and residual solvents, aggregation assessment where relevant and lot-specific stability
Sterility, endotoxin and bioburden are separate released-lot claims
Appearance or HPLC area alone cannot establish identity, content or human suitability.
Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement
Available fills
Quote the fill and pack configuration you need
Reference SKUFillBase pack
BC22 mg10 vials
BC55 mg10 vials
BC1010 mg10 vials
BC2020 mg10 vials
Other format
Also available as a nasal spray (US stock)
10 mL nasal spray bottle
Besides lyophilized vials, BPC-157 is also supplied as a nasal spray solution, shipped from our US stock.
Strengths
2 mg · 5 mg · 10 mg
Bottle sizes
10 mL or 20 mL
Minimum order
10 bottles per strength and bottle size
Ships from
Our US stock
Capsules · US stock
Also supplied as capsules
BPC-157 is also supplied in capsule bottles, held in our US stock and shipped within the US. Ask our sales team for a quote. For research use only.
Strength
Ask for the strengths in stock
Ships from
Our US stock
Handling
Plan storage before the parcel arrives
Follow the released lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, buffer, concentration, container and any post-reconstitution hold time require stability-indicating evidence for the exact free-base or acetate form. Do not assign a universal frozen shelf life or 28-day solution period.
State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.
Buyer FAQ
Terms to settle before the purchase order
Can a buyer arrange third-party testing?+
Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.
What if my own lab test shows the product is out of specification?+
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Does HPLC purity prove peptide content?+
No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.
How should material be stored after delivery?+
Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.
How are payment terms handled?+
Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.
Why must the testing laboratory understand peptide chemistry?+
Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.
Selected sources
Literature behind the research context
Identity: PubChem CID 9941957, sequence GEPPPGKPADDAGLV, formula C₆₂H₉₈N₁₆O₂₂ and molecular weight approximately 1419.5 Da. Regulatory context: FDA official July 23–24, 2026 PCAC meeting page and BPC-157 briefing document; advisory review is non-binding and not approval. Anti-doping context: official WADA 2026 Prohibited List, S0. Evidence context includes the 2022 rat/beagle-dog pharmacokinetic study, PMC9794587; preclinical gastrointestinal and tissue-repair literature; toxicology literature; and the 2025 report PMID 40131143 involving only 2 healthy adults. Vendor and community protocols were excluded.
01
Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications
Current Neuropharmacology · 2016 · peer-reviewed review article
ClinicalTrials.gov (U.S. National Library of Medicine trial registry) · 2015 · clinical trial registry entry (Phase I, randomized, placebo-controlled, pilot)
What is established about BPC-157 identity and sequence?+
The free peptide is a linear 15-residue sequence, GEPPPGKPADDAGLV, recorded by PubChem CID 9941957 with formula C₆₂H₉₈N₁₆O₂₂ and molecular weight about 1419.5 Da. Identity still requires the offered lot’s terminal state, salt or counterion, theoretical and observed intact mass, sequence evidence and quantitative content. Sequence composition alone does not prove unusual oral, gastric or serum stability.
How should free base and acetate be specified?+
Do not rely on the name BPC-157 alone. The quotation and COA should state free base versus acetate, CAS or registry mapping where applicable, formula and molecular-weight basis, counterion content, water, peptide assay, intact mass, chromatographic method and impurity profile. Activity per gross vial mass cannot be assumed equivalent when salt, water and peptide-content bases differ.
Is co-formulation with TB-500 or other peptides established?+
No controlled peer-reviewed study identified a clinically validated BPC-157/TB-500 combination or universal solution compatibility. Co-lyophilization is a separate formulation-development project requiring identity, ratio, content uniformity, impurity, stability and container-closure evidence for the actual blend. Marketing popularity is not evidence of synergy or stability.
